Mylan announces quarterly loss due to Morgantown restructuring

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/zoom-zoom)
(Image: Getty/zoom-zoom)

Related tags: Mylan, Fda, Food and drug administration, Earnings call

Troubleshooting in Mylan’s Morgantown facility, after a US FDA warning, has hurt the company’s first quarter results.

Mylan reported a net loss of $25m (€22.2m) compared to last year’s profit of $87.1m.

According to the company’s CEO, Heather Bresch, “The large swing is due to the timing of key product launches, working capital investments [...] as well as continued positive progress on the Morgantown remediation.”

In November 2018, the US Food and Drug Administration (FDA) issued the company a warning letter following a Form 483 with thirteen observations​ due to a “lack of appropriate oversight”​ by Mylan’s Quality Unit at its facility in Morgantown, West Virginia.

The company then published a statement answering the FDA​, noting it will proceed in ‘comprehensive restructuring and remediation’ of the facility. At the same time, Mylan’s management informed investors​ that the restructure will force a decreased production in the facility.

Bresch said that the Morgantown remediation program cost the company approximately $70m. However, she pointed out the company’s top line results fell “slightly softer against our own expectation”, ​announcing $2.5bn in revenue versus $2.7bn consensus.

Answering investors during 2019 first-quarter earnings’ announcement, Mylan’s CFO, Ken Parks, confirmed the company carried out a number of discontinuations throughout 2018 in order to ‘prune’ its portfolio and commented that this “certainly has played a big role in how much we've seen year-over-year volume declination.”

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us


View more